Investment Analysts’ Recent Ratings Updates for Myriad Genetics (MYGN)

Several analysts have recently updated their ratings and price targets for Myriad Genetics (NASDAQ: MYGN):

• 3/4/2025 – Myriad Genetics had its price target lowered by analysts at Piper Sandler from $14.00 to $11.50. They now have a “neutral” rating on the stock.
• 3/3/2025 – Myriad Genetics had its price target lowered by analysts at Bank of America Co. from $13.00 to $11.00. They now have an “underperform” rating on the stock.
• 3/1/2025 – Myriad Genetics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 2/25/2025 – Myriad Genetics had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $19.00 price target on the stock, down previously from $27.00.
• 2/25/2025 – Myriad Genetics had its price target lowered by analysts at UBS Group AG from $18.00 to $16.00. They now have a “neutral” rating on the stock.
• 2/20/2025 – Myriad Genetics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 2/12/2025 – Myriad Genetics is now covered by analysts at Craig Hallum. They set a “buy” rating and a $29.00 price target on the stock.
• 1/30/2025 – Myriad Genetics had its price target lowered by analysts at Piper Sandler from $24.00 to $14.00. They now have a “neutral” rating on the stock.
• 1/28/2025 – Myriad Genetics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a “buy” rating on the stock.
• 1/16/2025 – Myriad Genetics had its “equal weight” rating reaffirmed by analysts at Stephens. They now have a $20.00 price target on the stock.
• 1/9/2025 – Myriad Genetics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Myriad Genetics Stock Down 3.2 %

MYGN opened at $10.18 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The business has a 50 day simple moving average of $12.95 and a 200-day simple moving average of $18.29. The stock has a market capitalization of $929.53 million, a P/E ratio of -7.83 and a beta of 1.79. Myriad Genetics, Inc. has a 12 month low of $9.76 and a 12 month high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). The business had revenue of $210.60 million during the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period in the prior year, the business earned ($0.12) earnings per share. On average, equities analysts anticipate that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Myriad Genetics

Hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new stake in shares of Myriad Genetics in the 3rd quarter valued at approximately $32,000. Sterling Capital Management LLC increased its stake in Myriad Genetics by 829.9% in the 4th quarter. Sterling Capital Management LLC now owns 2,864 shares of the company’s stock valued at $39,000 after purchasing an additional 2,556 shares in the last quarter. KBC Group NV increased its stake in Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock valued at $80,000 after purchasing an additional 3,334 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares in the last quarter. Finally, Meeder Asset Management Inc. increased its stake in Myriad Genetics by 588.4% in the 3rd quarter. Meeder Asset Management Inc. now owns 4,922 shares of the company’s stock valued at $135,000 after purchasing an additional 4,207 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.